In HR+, HER2− MBC patients with resistance to CDK4/6 inhibitors plus endocrine treatment, PIK3CA mutation testing on tumor tissue or circulating tumor cells is justified to select patients who could potentially benefit from alpelisib [71]. The gene discussed is CDK4; the disease is neoplasm.